

1 **Title:** Trends in Repeat Administration of Magnesium for an Exacerbation of Postpartum

2 Preeclampsia: A National Survey

3 **Authors**

4 Gabriela DELLAPIANA, MD¹

5 Keona THOMPSON, MD²

6 Kimberly D GREGORY, MD MPH^{1,3}

7 ¹Department of Obstetrics & Gynecology, Division of Maternal Fetal Medicine, Cedars-Sinai

8 Medical Center, Los Angeles, California, United States.

9 ²Department of Obstetrics & Gynecology, Cedars-Sinai Medical Center, Los Angeles, California,

10 United States.

11 ³The Helping Hands of Los Angeles Miriam Jacobs Chair in Maternal Fetal Medicine

12

13 **Disclosures:** K.D.G. receives funding from Helping Hand of Los Angeles Miriam Jacobs Chair in

14 Maternal Fetal Medicine and CTSI (UCLA CTSI 2UL1TR001881-06A1). The remaining authors

15 report no conflict of interest.

16 **Funding:** This research did not receive any specific grant from funding agencies in the public,

17 commercial, or not-for-profit sectors

18 **Corresponding Author:**

19 Gabriela Dellapiana, MD

20 Assistant Professor, Department of Obstetrics and Gynecology, Division of Maternal-Fetal

21 Medicine

22 Cedars-Sinai Medical Center

23 8635 W 3rd Street, Suite 160-W

24 Los Angeles, CA 90048

25 Gabriela.dellapiana@cshs.org

26 Office phone: 310-423-7417

27 Fax: 310-423-9939

28 **Background:**

29 Magnesium (Mg) infusion is first-line for seizure prophylaxis in preeclampsia with severe
30 features (PESF). Guidance is lacking regarding utility of an additional course of Mg for disease
31 exacerbation following completion of an initial course. We aimed to determine the national
32 trend among academic institutions for administration of a second course of Mg in patients with
33 an exacerbation of PESF.

34 **Methods:**

35 A REDCap survey querying response to clinical scenarios related to Mg administration was sent
36 to Maternal-Fetal Medicine program directors (or surrogate if no response) using publicly
37 available contact information. Participants received a \$10 incentive.

38 **Results:**

39 Responses were received from 66 of 95 institutions (69%), representing all 12 ACOG districts. An
40 institutional protocol for postpartum Mg was reported by 70% (N=46) of respondents. Overall,
41 68% (N=45) would give a second course of Mg for an exacerbation of PESF, with no geographic
42 variation (P=0.969). Most would administer a second course of Mg if the patient had a
43 headache (N=52, 79%) or blood pressure $\geq 180/120$ (N=35, 53%). The decision for a
44 second course of Mg was not influenced by worsening laboratory values, gestational age at
45 delivery, latency from delivery, or maternal demographics.

46 **Conclusions:**

47 Although there are no standardized guidelines for seizure prophylaxis in postpartum
48 exacerbations of PESF, this national survey suggests that most academic programs favor giving a
49 second course of Mg, especially in patients with headache or severe BP. A randomized trial

50 comparing outcomes in patients who did or did not receive an additional course of Mg is
51 warranted.

52 **Introduction:**

53 Eclampsia is a morbid pregnancy complication characterized by the sudden-onset of a
54 generalized tonic-clonic seizure in a patient with preeclampsia or gestational hypertension.
55 Eclampsia occurs in 2-3% of patients with preeclampsia with severe features (PESF) that goes
56 untreated.¹⁻³ Approximately 60% of cases of eclampsia occur antepartum, 20% intrapartum, and
57 20% postpartum.⁴ Among those cases occurring postpartum, 90% present within the first week
58 of delivery, but eclampsia can manifest up to 6 weeks after birth.⁵

59
60 Magnesium (Mg) sulfate infusion is the first-line treatment for the prevention of seizures in
61 patients with PESF, reducing the risk by 58%,^{2,6,7} and the American College of Obstetricians and
62 Gynecologists (ACOG) recommends completing 24 hours of Mg in the immediate postpartum
63 period for most patients.⁸ However, there is no guidance regarding whether or not a patient
64 would benefit from a second course of Mg therapy for seizure prophylaxis in the event of an
65 exacerbation of PESF after completion of the first course.

66
67 The purpose of this study is to determine the national trend for the administration or omission
68 of repeat Mg infusion in patients with an exacerbation of PESF by surveying Maternal-Fetal
69 Medicine (MFM) academic providers.

70

71 **Study Design:**

72 We conducted a voluntary, cross-sectional, web-based, self-administered, nationwide REDCap
73 survey of leaders in perinatology to elicit practice habits regarding repeat administration of Mg.

74 REDCap is a secure web application for managing online surveys. Ethical approval was obtained
75 from the Institutional Review Board. Invited participants included current MFM fellowship
76 directors from all United States-based programs solicited via email using publicly available
77 contact information. If there was no response after 4 mailings, a surrogate program
78 representative was invited using the institutional public website until a response from that
79 institution was received or a maximum of three MFM faculty were approached. If no response
80 was received from a faculty member, a final attempt was made to get a response from an MFM
81 fellow currently at the institution. The fellow was identified from a distribution list of MFM
82 fellows available to one of the investigators. If no response after five individuals had been
83 approached, the program was considered as nonrespondent.

84
85 The survey included 16 questions with various clinical scenarios and was designed to be
86 completed in 10 minutes or less. The first page addressed informed consent. Access was limited
87 to those who received a personalized link. Technical functionality of the survey was tested prior
88 to distribution. Respondents were able to review or change answers prior to submission.
89 Surveys were marked complete if all required questions were answered. Once a completed
90 survey was submitted, edits were no longer available, ensuring a single response per
91 participant. The only demographic data requested was geographic region (as determined by
92 ACOG district; Table 1) and institution (to track response rate). Only completed surveys were
93 included in the analysis. Each survey response was de-identified and assigned a study ID that
94 was exclusively used when sorting and analyzing data. The survey was accessible from March

95 2022 to June 2022. Participants received a \$10 electronic gift card incentive upon completion of
96 the survey.

97
98 Survey data was analyzed with STATA IC 16.1 (College Station, TX). Data was analyzed using chi-
99 square test and fisher's exact test as appropriate. Statistical significance was determined by
100 $\alpha=0.05$.

101

102 **Results:**

103 Responses were received from 66 of 95 institutions contacted (69% response rate), representing
104 all 12 ACOG districts. MFM program directors comprised 62% of responses (N=41), MFM faculty
105 24% (N=16), and MFM fellows 14% (N=9). A standard institutional protocol for postpartum Mg
106 was reported by 70% (N=46) of respondents with no difference by geographic region (P=0.666).
107 When asked, "would you give a second course of Mg for seizure prophylaxis for an exacerbation
108 of PESF after completion of the first course," 68% (N=45) of respondents reported they would
109 (Re-Mg group) and 32% (N=21) reported they would not (No-Mg group). Again, no geographic
110 variation was seen in decision to administer a second course of Mg (P=0.969; Figure 1).

111

112 The leading clinical scenario in which respondents would choose to administer a second course
113 of Mg was sustained severe hypertension with the coexistence of a headache. For MFMs in the
114 Re-Mg group, presence of a headache was an influencing factor for 98%. Latency from delivery
115 was secondarily influential in that 53% would give a second course of Mg for a headache and
116 hypertension on postpartum day 2, but 96% would on postpartum day 7 and 89% would on

117 postpartum day 14; only 53% would on postpartum week 3-6. Even among MFMs who originally
118 stated they would not give a second course of Mg, the presence of a headache influenced 62%
119 to re-administer Mg with the highest proportion of respondents choosing to do so on
120 postpartum day 2 (38%) or postpartum day 7 (33%).

121
122 The next most common reason respondents elected to administer a second course of Mg was
123 based on increasing severity of hypertension (Figure 2). In the Re-Mg group, 47% would give a
124 second course of Mg for systolic blood pressure (SBP) ≥ 160 and/or diastolic blood pressure
125 (DBP) ≥ 110 and 62% would for SBP ≥ 180 and/or DBP ≥ 120 , whereas 36% reported they would
126 give a second course regardless of hypertension severity. Of the respondents who originally
127 stated they would not give a second course, 14% and 33% opted to readminister Mg for
128 SBP ≥ 160 and/or DBP ≥ 110 and SBP ≥ 180 and/or DBP ≥ 110 , respectively.

129
130 In the Re-Mg group, respondents identified increasing liver function tests (69%), decreasing
131 platelet count (60%), and increasing serum creatinine (51%) as other stimuli for choosing to
132 readminister Mg; changes in laboratory values did not sway the No-Mg group. In both the Re-
133 Mg and No-Mg groups, the decision for a second course of Mg was not influenced by maternal
134 age, race/ethnicity, body mass index, parity, or gestational age at delivery.

135

136 **Discussion:**

137 Our study explored the practice habits of MFM faculty from academic institutions around the
138 country regarding if and under what circumstances they would administer a second course of

139 Mg for an exacerbation of PESF. Although no standardized guidelines exist, the national trend
140 among academic leaders of obstetric care favors giving a second course of Mg.
141
142 Providers queried in our study were most inclined to recommend additional Mg in patients with
143 a headache, corresponding to a previously well-documented risk factor for eclampsia.
144 Systematic reviews have shown that headache precedes seizure activity in up to 80% of
145 patients.^{4,9} Respondents were also more motivated to prescribe a second course of Mg with
146 increasing severity of hypertension. Notably, data has shown that severe hypertension is more
147 strongly correlated with antepartum eclampsia than postpartum eclampsia,¹⁰ and up to 25% of
148 patients with eclamptic seizure are normotensive immediately preceding convulsions.¹¹
149
150 We only identified one other study evaluating repeat administration of postpartum Mg. Isler, et
151 al¹² evaluated 500 patients with preeclampsia and identified 7.6% who received reinstatement of
152 postpartum Mg. In their cohort, patients with chronic hypertension complicated by
153 superimposed preeclampsia were the most likely to receive additional Mg therapy compared to
154 other hypertensive disorders, followed by patients delivered at less than 34 weeks' gestational
155 age. This is in contrast to our findings; 64% of the Re-Mg group stated that the diagnosis of
156 chronic hypertension would make them *less* likely to readminister Mg, and 34% indicated that
157 chronic hypertension played no role in the decision to repeat prophylaxis. Additionally, 93% of
158 the Re-Mg group and 100% of the No-Mg group indicated that gestational age at delivery had
159 no influence on their choice.
160

161 Findings from this study must be evaluated in the context of its limitations. Firstly, we sampled a
162 relatively small sample size compared to the total number of practicing MFM physicians in the
163 country. However, our respondents represent all 12 ACOG districts and are leaders in academic
164 medicine who train obstetric residents and MFM fellows. Studies suggest that providers
165 continue to practice the way they were trained, and that changes in practice can take up to 17
166 years to become widely implemented despite significant evidence supporting alterations in
167 treatment protocols.¹³⁻¹⁴

168
169 Secondly, not all Mg-prescribing obstetrical providers were included in the investigation (e.g.,
170 specialist obstetricians, midwives, and family medicine practitioners), but likely they are
171 impacted by interdisciplinary protocols and recommendations from MFM consultants.

172

173 **Perspectives**

174 There is a paucity of evidence regarding the need for or efficacy of repeat administration of Mg
175 sulfate for seizure prophylaxis in patients with a postpartum exacerbation of preeclampsia with
176 severe features. That said, a majority of MFM's recommend a second course of Mg therapy in a
177 patient presenting with headache or progressively severe hypertension. A randomized trial
178 comparing outcomes in patients with an exacerbation of preeclampsia stratified by
179 administration or omission of an additional course of Mg is warranted but unlikely given the
180 large sample size needed to assess for the rare event of eclampsia.

181

182 **Acknowledgements:** Thank you to Samia Saeb, MPH, for assistance with utilizing REDCap.

183

184 **Disclosures:** K.D.G. receives funding from Helping Hand of Los Angeles Miriam Jacobs Chair in
185 Maternal Fetal Medicine and CTSI (UCLA CTSI 2UL1TR001881-06A1). The remaining authors
186 report no conflict of interest.

187

188 **Novelty and relevance**

189 1. What is new?

190 a. This is the first large-scale survey to our knowledge to ascertain whether
191 academic perinatologists administer or omit an additional magnesium infusion
192 for seizure prophylaxis following completion of the initial course in patients with
193 exacerbation of preeclampsia.

194 2. What is relevant

195 a. Hypertensive disorders of pregnancy are a leading cause of maternal morbidity
196 and mortality
197 b. There is currently no guidance for utility or clinical necessity of an additional
198 course of magnesium for seizure prophylaxis

199 3. Clinical/pathophysiological implications


200 a. In the data-free zone that is how to optimally manage an exacerbation of
201 preeclampsia with severe features in the postpartum period, our study provides
202 the national trend among leaders at academic institutions (suggestive of the
203 expert opinion).

204 **References:**

- 205 **1.** Coetzee EJ, Dommissie J, Anthony J. A randomized controlled trial of intravenous
206 magnesium sulphate versus placebo in the management of women with severe pre-
207 eclampsia. *Br J Obstet Gynaecol.* 1998 Mar;105(3):300-3
- 208 **2.** Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith D; Magpie Trial
209 Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from
210 magnesium sulphate? The Magpie Trial: a randomized placebo-controlled trial. *Lancet.*
211 2002 Jun 1;359(9321):1877-90
- 212 **3.** Belfort MA, Anthony J, Saade GR, Allen Jr JC; Nimodipine Study Group. A comparison of
213 magnesium sulfate and nimodipine for the prevention of eclampsia. *N Engl J Med.* 2003
214 Jan 23;348(4):304-11
- 215 **4.** Berhan Y, Berhan A. Should magnesium sulfate be administered to women with mild
216 pre-eclampsia? A systematic review of published reports on eclampsia. *J Obstet*
217 *Gynaecol Res.* 2015 Jun;41(6):831-42
- 218 **5.** Al-Safi Z, Imudia AN, Filetti LC, Hobson DT, Bahado-Singh RO, Awonuga AO. Delayed
219 postpartum preeclampsia and eclampsia: demographics clinical course, and
220 complications. *Obstet Gynecol.* 2011 Nov;118(5):1102-1107
- 221 **6.** Duley L, Henderson-Smart DJ, Chou D. Magnesium sulphate versus phenytoin for
222 eclampsia. *Cochrane Database Syst Rev.* 2010(10):CD000128
- 223 **7.** The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with
224 eclampsia? Evidence from the Collaborative Eclampsia Trial. *Lancet.*
225 1995;345(8963):1455-63


- 226 **8.** The American College of Obstetricians and Gynecologists, Committee on Practice
227 Bulletins – Obstetrics. Gestational hypertension and preeclampsia. *Obstet Gynecol.*
228 2020;135(6):e237-260
- 229 **9.** Cooray SD, Edmonds SM, Tong S, Samarasekera SP, Whitehead CL. Characterization of
230 symptoms immediately preceding eclampsia. *Obstet Gynecol.* 2011 Nov;118(5):995-999
- 231 **10.** Mattar F, Sibai BM. Eclampsia. VIII. Risk factors for maternal morbidity. *Am J Obstet*
232 *Gynecol.* 2000 Feb;182(2):307-12
- 233 **11.** Bartal MF, Sibai BM. Eclampsia in the 21st century. *Am J Obstet Gynecol.* 2022
234 Feb;226(2S):S1237-S1253
- 235 **12.** Isler CM, Barrilleaux PS, Rinehart BK, Magann EF, Martin Jr JN. Repeat postpartum
236 magnesium sulfate administration for seizure prophylaxis: is there a patient profile
237 predictive of need for additional therapy? *J Matern Fetal Neonatal Med.* 2002
238 Feb;11(2):75-9
- 239 **13.** Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the
240 quality chasm: a new health system for the 21st century. Washington (DC): National
241 Academies Press (US); 2001. Executive Summary. Available from:
242 <https://www.ncbi.nlm.nih.gov/books/NBK22227>
- 243 **14.** Westfall JM, Mold J, Fagnan L. Practice-based research – “Blue Highways” on the NIH
244 roadmap. *JAMA.* 2007 Jan 24;297(4):403-6

245 **Figure 1. Percent of Maternal-Fetal Medicine physicians who would elect to give a**
246 **second course of magnesium for an exacerbation of postpartum preeclampsia by**
247 **ACOG district**



248
249 ACOG, American College of Obstetricians and Gynecologists

250 **Figure 2. Percentage of Respondents Whose Decision for a 2nd Course of Magnesium**
 251 **for an Exacerbation of PEFW would be influenced by:**



252
 253
 254 *PEFW*, preeclampsia with severe features; *LFTs*, liver function tests; *SBP*, systolic blood
 255 pressure; *DBP*, diastolic blood pressure, *BMI*, body mass index

256
257

Table 1. Geographic distribution by ACOG district

District	States Included
I	Connecticut, Maine, Massachusetts, Rhode Island, and Vermont
II	New York
III	Delaware, New Jersey, and Pennsylvania
IV	District of Columbia, Georgia, Maryland, North Carolina, South Carolina, Virginia, and West Virginia
V	Indiana, Kentucky, Ohio, and Michigan
VI	Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, and Wisconsin
VII	Alabama, Arkansas, Kansas, Louisiana, Mississippi, Missouri, Oklahoma, and Tennessee
VIII	Alaska, Arizona, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming
IX	California
AFD	Armed Forces District
XI	Texas
XII	Florida

258

ACOG, American College of Obstetricians and Gynecologists